Media stories about SCYNEXIS (NASDAQ:SCYX) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. SCYNEXIS earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.9777355215519 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

A number of equities analysts have issued reports on the company. ValuEngine upgraded SCYNEXIS from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, Guggenheim started coverage on SCYNEXIS in a report on Tuesday, October 24th. They issued a “buy” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.43.

Shares of SCYNEXIS (NASDAQ:SCYX) traded up $0.02 on Friday, hitting $1.84. The company had a trading volume of 105,600 shares, compared to its average volume of 314,408. SCYNEXIS has a 12 month low of $1.52 and a 12 month high of $3.72. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.43. The company has a market cap of $53.38, a PE ratio of -2.27 and a beta of 0.36.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Tuesday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. SCYNEXIS had a negative return on equity of 64.12% and a negative net margin of 8,569.46%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at


SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Insider Buying and Selling by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with's FREE daily email newsletter.